¶ CB1
¶ Definition
Cannabinoid receptor 1 (CB1) is a G-protein coupled receptor (GPCR) predominantly expressed on presynaptic terminals throughout the central nervous system, with highest density in hippocampus, basal ganglia, cerebellum, and periaqueductal gray (PAG). CB1 mediates the effects of endogenous cannabinoids (anandamide, 2-AG) and exogenous cannabinoids (THC) through Gi/o protein coupling, regulating neurotransmitter release, pain modulation, memory consolidation, appetite, mood, and neuroprotection. CB1 is the most abundant GPCR in the mammalian brain, with additional expression on immune cells, adipocytes, and hepatocytes.
¶ Picture It
Think of CB1 receptors as volume knobs installed before the speaker in your brain's communication network. Normal neural signaling is like turning up the speaker volume—neurotransmitters flood across the synapse. But CB1 sits on the presynaptic terminal (the side sending the message) and when activated by endocannabinoids, it turns the volume knob down before the message is sent. Instead of blocking the signal after it's already blasted out, CB1 prevents the neuron from releasing as much neurotransmitter in the first place.
When you're injured, your body produces 2-AG and anandamide—your endogenous "cannabis"—which float backward across the synapse (retrograde signaling) from the receiving neuron to hit these CB1 volume knobs on the sender. This turns down glutamate (excitatory signals), GABA (inhibitory signals), and norepinephrine (stress signals) depending on which neurons are involved. In the PAG pain control center, activating CB1 is like turning down the pain broadcast before it reaches your conscious awareness. But here's the catch: if you keep the volume knob at zero constantly (chronic cannabis use), the radio station eventually removes the knob entirely (receptor downregulation), and you need more and more signal just to hear anything (tolerance).
¶ Mechanism
CB1 receptor activation follows this cascade:
Endocannabinoid synthesis and retrograde signaling:
- Postsynaptic neuron depolarization → calcium influx → phospholipase C activation
- PLC cleaves membrane phospholipids → generates 2-AG (via diacylglycerol lipase) or anandamide (via N-acyl phosphatidylethanolamine-specific phospholipase D)
- Lipophilic endocannabinoids diffuse backward across synapse (retrograde transmission)
- Endocannabinoids bind presynaptic CB1 receptors
CB1 receptor signaling:
CB1 (Gi/o-coupled GPCR) → Gi/o protein dissociation → three parallel pathways:
Pain modulation pathway (PAG-specific):
CB1 activation in dorsolateral PAG → disinhibition of descending pathways → activation of rostroventral medulla → enkephalinergic neurons project to dorsal horn → presynaptic inhibition of nociceptive terminals → release of endogenous opioids → bind mu/delta opioid receptors → reduced pain transmission to thalamus
Anti-inflammatory effects:
CB1 on microglia → reduced NF-κB nuclear translocation → decreased IL-1β, TNF-α, IL-6 production → reduced neuroinflammation → protection against glutamate excitotoxicity
Metabolic effects:
CB1 on adipocytes → altered adiponectin secretion and lipogenesis
CB1 on hepatocytes → modulation of fatty acid oxidation and glucose metabolism
Receptor regulation:
Chronic agonist exposure → β-arrestin recruitment → CB1 internalization → endocytosis → lysosomal degradation or recycling → net downregulation (50-70% reduction in chronic users) → functional tolerance requiring 2-4 weeks abstinence for recovery
¶ Clinical Significance
CB1 is central to understanding the body's endogenous pain resolution mechanisms and represents a key component of Metamodel 5 (the evolutionary expectation of intermittent stressors followed by recovery). The endocannabinoid system functions as an "on-demand" protective mechanism activated during injury, stress, and inflammation—evolutionary intermittent challenges that should resolve.
Clinical relevance by condition:
-
Chronic pain: Endocannabinoid deficiency contributes to pain chronification. Clinical observation: patients with fibromyalgia, migraine, and IBS show reduced endocannabinoid tone. Anandamide levels
.5 ng/mL correlate with treatment-resistant pain states. -
Anxiety and depression: Low-dose CB1 activation (via endocannabinoid enhancement) is anxiolytic through GABAergic modulation in amygdala. High-dose exogenous activation (THC >10mg) paradoxically increases anxiety via excessive glutamate suppression in prefrontal cortex. Endocannabinoid deficiency linked to treatment-resistant depression—particularly relevant given CB1's regulation of BDNF expression in hippocampus.
-
Neuroinflammation: CB1 activation on microglia shifts from M1 (pro-inflammatory) to M2 (resolution) phenotype. Relevant for MS, Alzheimer's, traumatic brain injury. CB1 agonism reduces microglial activation markers by 40-60% in animal models.
-
Metabolic dysfunction: Peripheral CB1 (liver, adipose, muscle) contributes to insulin resistance when chronically activated. Explains why chronic cannabis users show dysregulated glucose metabolism despite CNS appetite stimulation. Therapeutic window requires CNS-selective vs peripheral-selective modulation.
Intervention implications:
- Enhance endocannabinoid tone through substrates: omega-3 fatty acids (EPA/DHA provide arachidonic acid for anandamide synthesis), PEA (entourage effect via PPAR-α)
- Reduce endocannabinoid degradation: FAAH inhibitors (under development), natural FAAH modulators (oleic acid, curcumin)
- Lifestyle: exercise acutely increases anandamide ("runner's high" is partially CB1-mediated), cold exposure, intermittent fasting
- Avoid chronic exocannabinoid use in vulnerable populations (adolescents with developing hippocampus, patients with psychosis risk)
Connection to evolutionary mismatch: The endocannabinoid system evolved for acute stress resolution (injury, infection, social stress). Chronic activation—whether through persistent modern stressors or exogenous cannabinoids—leads to system exhaustion (downregulation), mirroring cortisol resistance and insulin resistance as examples of allostatic load.
¶ Key Facts
- CB1 is the most abundant GPCR in the brain with ~10-fold higher expression than dopamine receptors
- Highest CB1 density: hippocampus (memory), basal ganglia (movement), cerebellum (coordination), PAG (pain modulation), amygdala (emotion)
- 2-AG is 170-fold more abundant than anandamide in brain tissue; 2-AG is the primary endogenous CB1 agonist
- CB1 activation in PAG reduces pain perception by 40-60% through descending inhibition
- Chronic cannabis use (daily for >6 months) causes 50-70% CB1 receptor downregulation measurable via PET imaging
- CB1 recovery timeline: 2 days abstinence shows 10% recovery, 4 weeks shows ~80% recovery, full normalization requires 6-8 weeks
- Anandamide has dual activity: CB1 agonist + TRPV1 agonist (biphasic dose-response in pain)
- CB1 is present on 30% of GABAergic interneurons and 70% of glutamatergic terminals in cortex
- Exercise increases anandamide by 30-50% within 30 minutes; effect lasts 1-2 hours post-exercise
- THC binding affinity to CB1: Ki = 10-40 nM; anandamide: Ki = 89 nM; 2-AG: Ki = 472 nM
- Peripheral CB1 blockade improves metabolic parameters without CNS effects (rimonabant toxicity was due to CNS penetration)
- CB1 expression begins at embryonic day 14 in rodents; prenatal THC exposure permanently alters CB1 development
¶ Connections
- CB2 receptors — complementary cannabinoid receptor primarily on immune cells (spleen, lymph nodes, macrophages); CB2 mediates peripheral anti-inflammatory effects without psychoactivity, while CB1 dominates CNS signaling
- 2-AG — most abundant endocannabinoid, synthesized on-demand from membrane arachidonic acid via diacylglycerol lipase; primary full agonist at CB1 (unlike partial agonist anandamide)
- anandamide — first discovered endocannabinoid ("ananda" = bliss in Sanskrit); partial CB1 agonist with additional TRPV1 activity; rapidly degraded by FAAH enzyme (half-life <5 minutes)
- PAG — periaqueductal gray contains dense CB1 expression; CB1 activation here triggers descending pain inhibition via rostroventral medulla projections; key site for endogenous analgesia
- descending pain modulation — CB1 in PAG is essential component; endocannabinoids released during injury activate this top-down pain suppression pathway integrating with opioid systems
- exocannabinoids — external cannabinoids (THC, CBD); THC is CB1 agonist producing psychoactivity; CBD is negative allosteric modulator at CB1, opposing THC effects and reducing anxiety/psychosis risk
- TRPV1 — anandamide activates both CB1 and TRPV1; this dual activity creates biphasic dose-response in pain (low doses analgesic via CB1, high doses hyperalgesic via TRPV1)
- TRPA1 — CB1 signaling modulates TRPA1 sensitivity on nociceptors; endocannabinoid tone reduces TRPA1-mediated inflammatory pain and neurogenic inflammation
- hippocampus — highest CB1 density in brain; CB1 activation impairs short-term memory consolidation (accounts for THC-induced memory deficits); regulates adult neurogenesis in dentate gyrus
- BDNF — CB1 signaling bidirectionally regulates BDNF expression; acute CB1 activation increases BDNF (neuroprotective), chronic activation decreases BDNF (associated with depression/cognitive decline)
- neuroinflammation — CB1 on microglia and astrocytes suppresses pro-inflammatory phenotypes; reduces IL-1β, TNF-α, IL-6 secretion; promotes microglial shift from M1 to M2 phenotype
- microglia — CB1 receptors on microglia modulate activation state; CB1 agonism reduces microglial proliferation and cytokine production during neuroinflammation, protecting against excitotoxicity
- anxiety — CB1 modulation in amygdala and prefrontal cortex regulates anxiety responses; low-dose activation anxiolytic (via GABAergic suppression in amygdala), high-dose anxiogenic (excessive PFC suppression)
- depression — endocannabinoid system dysfunction implicated in major depression; CB1 regulates stress responses via HPA axis modulation; CB1 deletion in animal models produces depression-like behavior
- chronic pain — endocannabinoid deficiency syndrome proposed for fibromyalgia, migraine, IBS; reduced CB1 signaling contributes to central sensitization; therapeutic target for neuropathic and inflammatory pain
- PEA — palmitoylethanolamide enhances anandamide signaling through "entourage effect"; increases CB1 activation indirectly via PPAR-α modulation and FAAH inhibition
- omega-3 fatty acids — EPA and DHA are direct substrates for endocannabinoid synthesis; omega-3 supplementation increases brain anandamide and 2-AG levels by 20-40%; low omega-3 status reduces endocannabinoid tone
- dopamine — CB1 receptors on dopaminergic terminals in ventral tegmental area and nucleus accumbens modulate dopamine release; involved in reward processing, motivation, addiction pathways
- HPA axis — CB1 activation suppresses HPA axis activity; reduces CRH release from paraventricular nucleus, decreases cortisol output; endocannabinoid deficiency associated with HPA dysregulation
- glutamate — CB1 on glutamatergic terminals reduces excitatory transmission; prevents excitotoxicity during ischemia/inflammation; CB1 activation reduces glutamate release by 50-70%
- GABA — CB1 on GABAergic interneurons modulates inhibitory tone; CB1 activation reduces GABA release, leading to disinhibition (explains some anxiogenic effects at high doses)
- endocannabinoids — umbrella term for endogenous CB1/CB2 ligands; includes anandamide, 2-AG, and less studied molecules (noladin ether, virodhamine); produced on-demand during neuronal activity
- norepinephrine — CB1 reduces norepinephrine release from locus coeruleus; modulates stress responses and arousal; CB1 activation reduces sympathetic tone
- cortisol resistance — parallels CB1 downregulation as example of receptor resistance from chronic activation; both represent failed resolution of stress responses under evolutionary mismatch conditions
- allostatic load — chronic CB1 activation (via persistent stress or exogenous cannabinoids) increases allostatic load; receptor downregulation represents failed adaptation to chronic demand
¶ Module References
- Module 5 — endocannabinoid system in wound healing and pain resolution
- Module 6 — CB1 in descending pain modulation and chronic pain pathophysiology